Profiling of Circulating Immune Cells to Uncover Response Signatures to Anti-PD1 Immunotherapy in Melanoma Patients

Despite being standard of care, there are still many medical requirements related to immune checkpoint blocker based therapies such as identify patients susceptible to respond with the less adverse events, evaluate the clinical benefit of adjuvant treatment /risk of relapse and design new strategies for non-responder patients. Thus, this project aims at understanding the impact of anti-PD1 on the immune system through investigation of the phenotypic, functional, metabolic and transcriptomic profiles of circulating DC subsets and effectors in response to anti-PD1 therapy in melanoma patients. The primary objective of the study is to identify the biomarkers of response to anti-PD1 according to the type of patient before the start of the treatment.

NCT Number	NCT06154668
Lead Sponsor	University Hospital, Grenoble Collaborators: Etablissement Français du Sang
Conditions	Melanoma
Enrollment	707 participants
Start Date	2024-01-17
Primary Completion	2030-01 (estimated)
Study Completion	2031-01 (estimated)
Updated on ClinicalTrials.gov	2024-02-20